Insights

Innovative Platform EnGeneIC's proprietary EDV™ nanocell platform offers targeted delivery of chemotherapeutics and nucleic acids, providing a unique opportunity to collaborate with pharmaceutical companies seeking advanced cancer treatment technologies.

Global Presence Recent partnerships and clinical trials launched in Australia and Singapore indicate the company's expanding international footprint, making it a promising partner for global distribution and licensing opportunities.

Recognized Excellence Awarded the 2026 Breakthrough in glioblastoma Biotech Award, EnGeneIC's innovative approach has gained industry recognition, positioning it as a trailblazer for potential investment or strategic partnerships in cutting-edge oncology.

Strategic Collaborations Partnering with Singapore Institute of Advanced Medicine and ImmunityBio signals openness to co-developments, licensing, and joint ventures, creating multiple avenues for commercial expansion and product integration.

Funding & Market Entry With early-stage funding and plans for a NASDAQ listing, EnGeneIC is poised for growth, offering sales opportunities to investors and suppliers interested in breakthrough biotech innovations in the oncology space.

EnGeneIC Tech Stack

EnGeneIC uses 8 technology products and services including Font Awesome, OWL Carousel, jQuery, and more. Explore EnGeneIC's tech stack below.

Font Awesome

Font Scripts

OWL Carousel

Javascript Libraries

jQuery

Javascript Libraries

HSTS

Security

ZURB Foundation

UI Frameworks

X-Content-Type-Options

Web & Portal Technology

HTTP/3

Web & Portal Technology

Apache HTTP Server

Web Servers

EnGeneIC Email Formats	Example	Percentage
FLast@engeneic.com	JDoe@engeneic.com	97%
First.Last@engeneic.com	John.Doe@engeneic.com	1%
FMiddleLast@engeneic.com	JMichaelDoe@engeneic.com	2%

EnGeneIC Email Formats

Example

Percentage

FLast@engeneic.com

JDoe@engeneic.com

97%

First.Last@engeneic.com

John.Doe@engeneic.com

FMiddleLast@engeneic.com

JMichaelDoe@engeneic.com

Frequently Asked Questions

Where is EnGeneIC's headquarters located?

EnGeneIC's main headquarters is located at 11 Julius Avenue Level 4 North Ryde, New South Wales 2113 Australia. The company has employees across 3 continents, including OceaniaNorth AmericaAsia.

What is EnGeneIC's official website and social media links?

EnGeneIC's official website is engeneic.com and has social profiles on LinkedIn.

What is EnGeneIC's SIC code NAICS code?

EnGeneIC's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does EnGeneIC have currently?

As of June 2026, EnGeneIC has approximately 55 employees across 3 continents, including OceaniaNorth AmericaAsia. Key team members include Chief Financial Officer: B. H.Vice President Business Operations: S. P.Joint-Ceo And Director: J. M.. Explore EnGeneIC's employee directory with LeadIQ.

What industry does EnGeneIC belong to?

EnGeneIC operates in the Biotechnology Research industry.

What technology does EnGeneIC use?

EnGeneIC's tech stack includes Font AwesomeOWL CarouseljQueryHSTSZURB FoundationX-Content-Type-OptionsHTTP/3Apache HTTP Server.

What is EnGeneIC's email format?

EnGeneIC's email format typically follows the pattern of FLast@engeneic.com. Find more EnGeneIC email formats with LeadIQ.

When was EnGeneIC founded?

EnGeneIC was founded in 2001.

EnGeneIC

Q: What is EnGeneIC's official website and social media links?

EnGeneIC's official website is engeneic.com. EnGeneIC has social profiles on LinkedIn.

Q: How many employees does EnGeneIC have currently?

EnGeneIC has approximately 55 employees.

Q: What technology does EnGeneIC use?

EnGeneIC's tech stack includes Cloudflare, WordPress, X-XSS-Protection, Bootstrap, jQuery Waypoints.

Q: What is EnGeneIC's NAICS code?

EnGeneIC's NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Biotechnology ResearchNew South Wales, Australia51-200 Employees

EnGeneIC is an Australia-based biopharmaceutical company focused on advancing its EDV nanocell platform, which is designed to deliver chemotherapy drugs and functional nucleic acids directly to cancer cells. The EDV platform is described as a first-in-class Cyto-Immunotherapy system. Located in North Ryde, New South Wales, the company operates within the biotechnology research sector as a mid-sized organization developing targeted cancer therapies.

Its customers include other biopharma developers and research institutions seeking advanced delivery technologies to improve cancer treatment outcomes, with collaborations aimed at manufacturing and advancing EDV-based therapies. In June 2026, EnGeneIC was honored with the Breakthrough in glioblastoma Biotech Award at a Northwell Foundation gala in New York, highlighting recognition of its work in glioblastoma applications.

Insights

Similar companies to EnGeneIC

AsclepiX Therapeutics

AnaptysBio

Cardurion Pharmaceuticals

Alector

argenx

Annexon Biosciences

ImmuNext

Abpro

EnGeneIC Tech Stack

Media & News

EnGeneIC Ltd attended event Northwell Foundation Lenox Hill Neurosurgery Brain cancer gala on Jun 4th '26.

EnGeneIC Ltd received award Breakthrough in glioblastoma Biotech Award 2026 at Northwell Foundation, Lenox Hill Neurosurgery Brain Tumor Center Gala event on Jun 4th '26.

EnGeneIC Ltd launches australian trial for innovative cancer therapy.

SAM Holdings Corporation partners with EnGeneIC Ltd.

EnGeneIC Ltd partners with Singapore Institute of Advanced Medicine Holdings Pte Ltd.

EnGeneIC Ltd received financing of $5M in pre-IPO round on Jan 1st '22.

EnGeneIC Ltd partners with ImmunityBio, Inc..

EnGeneIC's Email Address Formats